.svg){kind=small}
Market Insights Snapshot
In July 2026, Amend Cannabis concentrated 65.98% of sales in Topical while Tincture & Sublingual accounted for 34.02%, a two-category mix that narrowed as Topical fell 47.73% month over month and Tincture & Sublingual declined 37.82% month over month. With average prices clustered at $37.51 and category-level pricing at 37.56 for Topical versus 37.42 for Tincture & Sublingual, the mix shift is driven far more by volume than price, and the 24-month brand sales change of -87.20% frames these double-digit monthly contractions as part of a longer retreat. The pattern implies the brand is over-indexed to Topical exposure in Missouri, and that dependency amplified July 2026 volatility rather than smoothing it via cross-category balance.
The simultaneous 47.73% Topical and 37.82% Tincture & Sublingual month-over-month drops, paired with a 65.98% to 34.02% category split, indicates concentration risk that reduces resilience to category-specific shocks and likely drags rank potential within Missouri Topical despite no published rank. Given the -87.20% 24-month sales change alongside near-parity pricing across both categories (37.56 versus 37.42), the July 2026 outcome points to distribution or assortment gaps rather than price positioning, implying the brand’s near-term positioning would benefit more from rebalancing mix and adding SKUs in steadier segments than from price moves.
Competitive Landscape
Amend Cannabis is ranked #9 in MO Topical for July 2026, improving 1 rank position from April 2026’s #10 while sitting 6 spots below its peak of #3 from July 2024; in contrast, Mary's Medicinals holds #1 with a 99.5% year-over-year sales increase and Escape Artists sits at #2 despite a 41.2% sales decline year over year. With Drool moving from #5 to #4 alongside an 18.2% YoY sales gain and Vlasic Labs advancing from #6 to #5 with 47.8% YoY growth, Amend Cannabis’s one-step rise over three months alongside a six-rank gap from its peak implies stabilization rather than a re-acceleration back toward the top tier.
Notable Products
CBD/THC 1:1 Amend Tincture (400mg CBD, 400mg THC) posted the steepest decline in July 2026 at -66.9% and fell to rank 3, while CBD/THC 1:1 Amend Infused Balm (250mg CBD, 250mg THC) dropped -45.4% yet held rank 1. Two Tincture & Sublingual SKUs sat in the top three at ranks 2 and 3 alongside a Topical at rank 1, and the 500mg Balm slid -14.2% to rank 4. The concentration of 1:1 CBD/THC formats across both Topical and Tincture suggests the brand is anchored in balanced wellness use-cases but is encountering dose-size elasticity that is pressuring higher-milligram tinctures.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
